Form 8-K CELGENE CORP /DE/ For: Nov 05

Go back to Form 8-K CELGENE CORP /DE/ For: Nov 05

Post-Q3 Selloff in Celgene (CELG) Probably Correction Following Recent Run - RBC

November 5, 2015 9:48 AM EST

RBC affirms Celgene Corp. (Nasdaq: CELG) at Outperform with a price target of $150 following Q3 results issued earlier.

Analyst Michael Yee noted that results for Celgene were relatively inline with expectations amid recently raised guiance when the company did its RCPT deal. The... More